Menopausal Symptomatic Relief | sciencenewsnet.in

Breaking News

New York State, City and Bronx Borough Officials Celebrate the 125th Anniversary of the Bronx Zoo

Silent flight edges closer to take off, according to new research

Novel material supercharges innovation in electrostatic energy storage

A Common Pathway in the Brain That Enables Addictive Drugs to Hijack Natural Reward Processing Has Been Identified by Mount Sinai

MSU expert to attend oral arguments in SCOTUS case that could turn homelessness into a crime

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science

Hubble Goes Hunting for Small Main Belt Asteroids

Two U Professors Selected as AAAS Fellows

New research finds electric vehicles depreciate faster than gas cars, but the trend is changing

19 Apr, 2024

Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes

June 11, 2022 sarah JonasResearch Results

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.